StaphVAX Nabi

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 48-50

  Jones, Taff ^a  

^a Intellivax International Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

STAPHYLOCOCCUS VACCINE; STAPHVAX;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; KIDNEY FAILURE; NONHUMAN; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; DRUG EFFECT; METABOLISM; METHODOLOGY; PHARMACEUTICS; STATISTICS; SYNTHESIS;

CLINICAL TRIALS; HUMAN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TECHNOLOGY, PHARMACEUTICAL; HUMANS;

EID: 0035985595     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. North America Biologicals Inc, expands early clinical programs to prevent Staphylococcus infections in immunocompromised patients
2. Nabi announces positive interim data from phase II dosing studies of StaphVAX
3. StaphVAX
4. Nabi announces initiation of Nabi-StaphVAX pivotal phase III trial
5. Kaiser Permanente runs pivotal clinical trial on promising new anti-staph vaccine
6. No safety issues in pivotal clinical trial of Nabi-StaphVAX
7. Nabi announces completion of data collection for Nabi StaphVAX pivotal trial
8. Nabi reports successful reduction in S Aureus bacteremias at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Nabi announces update on development plan for StaphVAX
10. Nabi initiates clinical trial to evaluate booster dose of Nabi StaphVAX
11. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A